Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

KYTHERA Biopharmaceuticals Inc (NASDAQ:KYTH)

During the Trading Day
74.72 -0.05 / -0.07%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
74.72 0.00 / 0.00%
Volume: 10.8K
Health Technology
Pharmaceuticals: Other

Company Description

KYTHERA Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The company's product candidate includes ATX-10 which is an injectable drug currently in Phase III clinical development for the reduction of submental fat. Its initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA.

Contact Information

KYTHERA Biopharmaceuticals, Inc.
30930 Russell Ranch Road
Westlake California 91362
P:(818) 587-4500
Investor Relations:
(818) 587-4559



Other institutional53.91%
Mutual fund holders29.14%
Individual stakeholders27.25%

Top Executives

Keith R. LeonardPresident, Chief Executive Officer & Director
Douglas A. RichVice President-Operations
John W. SmitherChief Financial Officer
Serge LichtsteinerVice President-Research
Paul F. LizzulMedical Director